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Abstract : Azithromycin （AZM） injection tends to increase injection site pain when 
administered in excess of 2 mg / ml.  As AZM is frequently used in combination 
therapies, it is expected to be administered at a high concentration in clinical 
use due to uid restrictions.  Therefore, in this study, the relation between AZM 
concentration and injection site pain was examined.  From January 2012 to July 
2017, we retrospectively investigated the medical records of patients who were 
administered AZM by injection at Showa University Fujigaoka Hospital.  Vascular 
pain was related to intensive care unit （ICU） administration （P＝0.003） compared 
with that in general wards and a long duration of administration （P＝0.002）.  The 
number of days of AZM injection should be kept as short as possible.  Given that 
the risk of injection site pain is increased in the ICU, we recommend switching to 
oral administration.  Further collection of safety data in patients on uid restriction 
is necessary, and high concentration AZM administration should be considered.
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Background
　Azithromycin（AZM） injection was approved in Japan in 2011.  Outside of Japan, the use of 
AZM is recognized in treating community-acquired pneumonia1, 2） and acute lung injury3）.  In a 
Japanese phase I trial, when AZM administration exceeded 2 mg / ml, the frequency of adverse 
events related to injection site pain tended to increase.
　In Japan, it is recommended to strictly observe an injection concentration of 1 mg / ml and an 
administration time of 2 h to avoid pain at the injection site.  However, in the aforementioned 
trial, the number of cases evaluated was as few as 10 patients, and the administration time 
was over 1 h.  Furthermore, tolerability has been confirmed for intravenous administration at 
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2 mg / ml / h in the United States4）.  It was also reported that injection site pain increases at 
concentrations above 4 mg / ml5）.  In Japan, a prospective trial in which concentrations of AZM 
of 2 mg / ml were injected was reported, but it included only 12 cases6）.
　In recent years, AZM has been administered to patients in the intensive care unit （ICU） 
in Japan7）, and no cases of phlebitis were reported.  However, 20％-70％ of patients receiving 
peripheral infusions have been reported to develop phlebitis8, 9）, and antimicrobial drugs 
themselves are regarded as a risk for phlebitis8-11）.
　Among antibiotics, erythromycin, a macrolide antibacterial drug, tends to cause phlebitis11）. 
Factors related to the occurrence of phlebitis include diabetes, female sex, work experience, 
catheter material, hemoglobin, drug pH, and osmotic pressure8-12）.
　As AZM is frequently used in combination with a beta-lactam agent, it is expected to be 
administered at a high concentration in clinical use due to restrictions on infusion volume. 
Therefore, in this study, we investigated the relation between AZM concentration and vascular 
pain during injection in our hospital.
Methods
　From January 2012 to July 2017, we retrospectively investigated the medical records of patients 
who were administered AZM by injection at Showa University Fujigaoka Hospital.  Patients 
under 18 years of age and those in whom AZM was administered via central venous catheter 
were excluded.
　The survey items were as follows: age, sex, body weight, ward （intensive care or general）, 
cardiac disease, electrocardiographic monitoring, administration time, number of administration 
days, AZM concentration administered by injection, laboratory data, vascular pain, and concurrent 
medications.  It was confirmed that the infusion time of AZM as administered by the pharmacist 
took over 2 h.
　For comparison between the two groups, Fisher’s direct stochastic method and t-test were 
used, and a significant difference was assumed at a 5％ risk rate.  The odds ratio and 95％ 
confidence interval were calculated as the expression rate of each factor.  All statistical analyses 
were performed with EZR （Saitama Medical Center, Jichi Medical University, Saitama, Japan）, 
which is a graphical user interface for R （The R Foundation for Statistical Computing, Vienna, 
Austria）.  More precisely, it is a modified version of R commander designed to add statistical 
functions frequently used in biostatistics13）.  This study was approved by the Institutional Review 
Board of Showa University Fujigaoka Hospital （Approval No. F2017C50）.
Results
Patient characteristics
　Patient characteristics are shown in Table 1.  The average age of the patients was 68.3 years, 
and 72% were male.  AZM was administered in the ICU in 40.6％ of the patients, 19.8% had 
a history of cardiovascular disease, and the electrocardiogram of 86.8％ of the patients was 
monitored.  AZM was administered at 1 mg / ml in 71.7％ of the patients and at a concentration 
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Table 1.  Patient’s characteristics（n＝ 106）
n（％）, mean ± SD
Age（years） 68.3 ± 16.4
Sex（male / female） 76 / 30
Body weight（kg） 57.4 ± 14.1
Clinical departments





　1 mg / ml 76（71.7）
　2 mg / ml 21（19.8）
　5 mg / ml  9（8.5）
Duration of azithromycin administration（days）  4.2 ± 2.2
　Over duration of 5 days 44（41.5）
30-day mortality 26（24.5）
WBC（×103 / ml） 11.4 ± 5.8
Hgb（g / dl） 12.0 ± 2.1
AST（IU / l） 59.8 ± 106.8
ALT（IU / l） 40.7 ± 56.9
BUN（mg / dl） 28.6 ± 27.4
Cr（mg / dl）  1.3 ± 1.4
Alb（g / dl）  3.1 ± 0.7




　Heparin or warfarin 21（19.8）
Combination of antibiotics













Injection site pain or erythema  9（8.5）
Background of patients receiving azithromycin （AZM） infusion.
71.7％ of patients were administered AZM at the concentration 
indicated on the package insert.
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exceeding the package insert directions in 28.3％.  The average number of treatment days was 
4.2, but 41.5％ of the patients underwent administration exceeding 5 days.  AZM alone was 
administered in 3.8％ of the patients.
Endpoint
　A total of nine patients （8.5％） were found to have vascular pain during AZM administration. 
All of them were administered AZM at an injection concentration of 1 mg / ml.  No medications 
were administered to hypersensitive patients who may have experienced skin disorders related 
to AZM injection.  The vascular pain in these nine patients was not judged to be caused by 
allergic reaction.
Univariate analysis
　Table 2 shows the results of univariate analysis depending on the presence or absence 
of vascular pain.  Factors found to be related to vascular pain were administration in the 
ICU （P＝0.003） versus that in general wards and long duration of administration （P＝
0.002）.  Hemoglobin, female sex, age ≥ 61 years, diabetes, cancer, immunological disorder, and 
administration concentration have been reported as factors causing vascular pain10）.  However, 
none of these factors was considered to be relevant in the vascular pain observed in the present 
study.
Discussion
　In this study, AZM administration at a high concentration over that recommended on the 
package insert was performed in 28.3％ of the patients.  Injection site pain was experienced 
in 8.5％ of all treated patients.  Similar to that in the present study, 5.9％ of patients with 
pneumonia who were administered AZM at a concentration of 1 mg / ml by injection in a 
Japanese phase Ⅲ trial experienced mild injection site pain14）.
　In the present study, no correlation between AZM concentration and injection site pain was 
found.  The only risk factors for injection site pain were administration in the ICU and duration 
of administration.  Compared with erythromycin, AZM is reported to be more neutral in pH, 
its osmotic pressure is close to 1, and less vascular pain is reported15）.  However, there is also a 
report suggesting problems of tolerability due to the influence of macrolides on endothelial cells, 
even at normal concentrations16）.  Various drugs are administered in the ICU17, 18）, and the use 
of antibiotics is ten times higher than in general wards18）.  Antibiotics that are prone to causing 
vascular pain are frequently used in combination.  During the study period, the pharmacist 
audited all orders for AZM administration, and adherence to injection over 2 h was strictly 
observed.  This strict observance of administration time was not mainly for the prevention of 
vascular pain but because slow administration does not cause QT prolongation that is observed 
with the rapid administration of macrolides.  When it is necessary to administer AZM at a high 
concentration, as in the previous reports7）, it may be possible to suppress injection site pain by 
setting the intravenous drip time to 2 h or more.
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　As a limitation of this research, various other factors causing vascular pain other than 
drug administration concentration （such as the location of blood vessels in which the drug is 
administered, length of the administration route, and nurse’s years of experience） were not 
confirmed.  Although AZM administered in the ICU can be affected by various other drugs, we 
think that there should be no objection to the necessity for caution.  In the ICU, patients are 
often managed in a sedated state, which may cause delay in their complaints of vascular pain19）. 
Therefore, we consider the results of this study to be reasonable.  As a serious side effect of 
Table 2.  Univariate analysis of risk factor in the injection site pain or erythema
Injection site pain or erythema
p valueYesn＝9 Non＝97
Age（years） 65.1 ± 16.0 68.6 ± 16.5 0.335
Sex（male / female） 6 / 3 70 / 27 0.710
Body weight（kg） 64.1 ± 16.7 56.8 ± 13.7 0.165
Hgb（g / dl） 12.5 ± 2.5 12.0 ± 2.1 0.511
Clinical department:
　Intensive care unit 8（88.9） 35（36.1） 0.003
　General wards 1（11.1） 62（63.9）
　Cardiac disease 4（44.4） 17（17.5） 0.074
Concentration of azithromycin
　1 mg / ml 9（100） 67（69.1） 0.230
　2 mg / ml 0（0） 21（21.6）
　5 mg / ml 0（0） 9（9.3）
Duration of azithromycin administration（days）  6.2 ± 2.4  4.0 ± 2.1 0.002
　Over duration of 5 days 7（77.8） 37（38.1） 0.032
Corticosteroids 1（11.1） 41（42.3） 0.084
Analgesic drug 3（33.3） 25（25.8） 0.696
Anticoagulant treatment
　Heparin or warfarin 3（33.3） 18（18.6） 0.377
Risk factors for erythema
　Gender（female） 3（33.3） 27（27.8） 0.703
　Age（over 61） 7（77.8） 70（72.2） 1.000
　Diabetes 3（33.3） 27（27.8） 0.710
　Cancer 0（0） 13（13.4） 0.597
　Immunocompromised 2（22.2） 9（9.3） 0.235
Combination of antibiotics







Univariate analysis of risk factor in the injection site pain or erythema.
Patients who complained of vascular pain tended to have an ICU stay and longer AZM administration days.
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AZM, eosinophilic pneumonia can develop, which may increase hypersensitivity.  Detailed data 
on hypersensitivity, such as the presence or absence of an elevated eosinophil level, were not 
examined, and thus, the possibility of an allergic potential for vascular pain cannot be denied. 
In the patients who did not develop vascular pain, it may have been masked by steroid 
administration.  Steroids are frequently administered to patients with severe pneumonia, so 
vasculitis may be suppressed.
　The number of days of AZM injection should be kept as short as possible.  It is 
recommended that doses over 5 days be administered under adequate observation, as there 
is little experience with dosing in Japan over 5 days.  Furthermore, this study suggested that 
administration for 5 days or more is a risk factor for vascular pain.  Confirmation of the reason 
for AZM administration is necessary to ensure that administration for indeterminate reasons 
is not performed.  Understanding that the risk of vascular pain increases in the ICU and 
considering the risks and benefits, we recommend switching to oral administration of AZM if 
possible.  Although injection site pain can be caused by various factors, it is still significant to 
consider patients with fluid volume restriction, and in such patients, AZM can be administered 
at a high concentration.  In this study as well, we believe that it is necessary to administer 
AZM more carefully as a large proportion of the patients in the high concentration group had a 
history of cardiovascular disease.  The results of this study showed that the AZM concentration 
was not a risk factor for injection site pain, but high concentration administration is not 
recommended in all cases.  In this study, all patients with vascular pain were dosed at 1 mg / ml. 
Although high concentrations are not recommended, AZM should be administered more carefully 
even at concentrations as per the package insert.  High concentration administration of AZM is, 
in fact, performed in Japan, and considering the previous reports, we need to collect additional 
safety data and reconsider the administration of AZM at a high concentration.
Conicts of interest disclosure
　The authors of this paper have no conflicts of interest to disclose.
References
1） Metersky ML, Ma A, Houck PM, et al. Antibiotics for bacteremic pneumonia: improved outcomes with macrolides 
but not uoroquinolones. Chest. 2007;131:466-473.
2） Asadi L, Sligl WI, Eurich DT, et al. Macrolide-based regimens and mortality in hospitalized patients with commu-
nity-acquired pneumonia: a systematic review and meta-analysis. Clin Infect Dis. 2012;55:371-380.
3） Walkey AJ, Wiener RS. Macrolide antibiotics and survival in patients with acute lung injury. Chest. 2012;141:1153-
1159.
4） Luke DR, Foulds G. Toleration of intravenous azithromycin. Ann Pharmacother. 1997;31:965-969.
5） Luke DR, Foulds G, Cohen SF, et al. Safety, toleration, and pharmacokinetics of intravenous azithromycin. Antimi-
crob Agents Chemother. 1996;40:2577-2581.
6） Uchida H, Oka H, Maeno T, et al. Tolerability of 2mg/mL administration of azithromycin in Japanese patients. Jpn 
J Chemother. 2014;62:382-384.
7） Haruki Y, Hagiya H, Sakuma A, et al. Investigation of intravenous azithromycin treatment safety when reducing 
213Study of Azithromycin-Induced Injection Site Pain
solvent for intensive care unit patients. Yakugaku Zasshi. 2015;135:987-990.（in Japanese）.
8） Monreal M, Quilez F, Rey-Joly C, et al. Infusion phlebitis in patients with acute pneumonia: a prospective study. 
Chest. 1999;115:1576-1580.
9） Webster J, Osborne S, Rickard CM, et al. Clinically-indicated replacement versus routine replacement of peripheral 
venous catheters. Cochrane Database Syst Rev. 2015;14:CD007798.（accessed 2019 Jul 3） Available from: https://
www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007798.pub4/epdf/full
10） Milutinovic D, Simin D, Zec D. Risk factor for phlebitis: a questionnaire study of nurses’ perception. Rev Lat Am 
Enfermagem. 2015;23:677-684.
11） Lanbeck P, Odenholt I, Paulsen O. Antibiotics differ in their tendency to cause infusion phlebitis: a prospective 
observational study. Scand J Infect Dis. 2002;34:512-519.
12） Nassaji-Zavareh M, Ghorbani R. Peripheral intravenous catheter-related phlebitis and related risk factors. Singapore 
Med J. 2007;48:733-736.
13） Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow 
Transplant. 2013;48:452-458.
14） Pzer. Rinsho koka. Kokyuki kansensho（haien）. Iyakuhin intabyu fuomu. 15inkan makuroraidokei kosei busshitsu 
seizai. Zithromac（R）tenteki jochuyo 500mg. Tenteki jochuyo azithromycin hydrate. Shohosen iyakuhin. June 2020 
11th ed. pp15-18. （accessed 2019 Jul 3） Available from: https://www.info.pmda.go.jp/go/pack/6149400D1021_1_14/
15） Howard KB, Blumenschein K, Rapp RP. Azithromycin versus erythromycin for community-acquired pneumonia: a 
cost-minimization analysis. Am J Health Syst Pharm. 1999;56:1521-1524.
16） Vorbach H, Armbruster C, Robibaro B, et al. Endothelial cell compatibility of azithromycin and erythromycin. J 
Antimicrob Chemother. 2002;49:407-409.
17） Roder BL, Nielsen SL, Magnussen P, et al. Antibiotic usage in an intensive care unit in a Danish university hospi-
tal. J Antimicrob Chemother. 1993;32:633-642.
18） Malacarne P, Rossi C, Bertolini G. Antibiotic usage in intensive care units: a pharmaco-epidemiological multicentre 
study. J Antimicrob Chemother. 2004;54:221-224.
19） Ratcliffe AT, Ismail KM. Intravenous macrolide use: a reminder of the dangers of rapid infusion rates. J Clin 
Anesth. 2012;24:602-603.
［Received July 11, 2019 : Accepted March 12, 2020］
